Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Revolution Medicines, Inc. - Common Stock (NQ:RVMD)

211.38 UNCHANGED

Streaming Delayed Price Updated: 4:00 PM EDT, Aug 25, 2026 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	1,039
Open	211.38
Bid (Size)	208.00 (100)
Ask (Size)	214.75 (100)
Prev. Close	211.38
Today's Range	211.38 - 211.38
52wk Range	35.62 - 220.34
Shares Outstanding	106,313,250
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Billionaire Stanley Druckenmiller Continues to Load Up on Revolution Medicines. Does He Know Something Wall Street Doesn't? ↗

August 25, 2026

One of the most successful investors ever really likes this up-and-coming biotech stock.

Via The Motley Fool

GLP-1 Drugs Are Huge. These 2 Stocks Are Tapping Into an Even Bigger Opportunity ↗

August 24, 2026

Could these 2 stocks outperform most GLP-1-focused companies over the medium term?

Via The Motley Fool

Performance

YTD	+167.5%	+167.5%
1 Month	+12.4%	+12.4%
3 Month	+36.5%	+36.5%
6 Month	+101.6%	+101.6%
1 Year	+492.6%	+492.6%

More News

Revolution Medicines (RVMD) Q2 2026 Earnings Call Transcript ↗

August 12, 2026

Via The Motley Fool

Revolution Medicines (NASDAQ:RVMD) Misses Q2 Estimates, Yet FDA Accepts Daraxonrasib Application ↗

August 05, 2026

Via Chartmill

Revolution Medicines (NASDAQ:RVMD) Flashes Strong Technical Breakout Setup ↗

July 30, 2026

Via Chartmill

Meet the Vanguard ETF That's Crushing the S&P 500 and Nasdaq-100 Despite Not Owning Micron, Sandisk, or Any of the "Magnificent Seven" Stocks ↗

August 18, 2026

Via The Motley Fool

Here’s How Much You Would Have Made Owning Revolution Medicines Stock In The Last 5 Years ↗

August 07, 2026

Via Benzinga

Revolution Medicines Q2 Earnings Call Highlights ↗

August 06, 2026

Via MarketBeat

Billionaire Stanley Druckenmiller Bought This Biotech Stock That Has Surged 400%. Is It Still a Buy? ↗

August 03, 2026

Via The Motley Fool

Why Billionaire Stanley Druckenmiller and Wall Street Analysts Love This Biotech Stock ↗

August 02, 2026

Via The Motley Fool

Meet the Stock That's Obliterating Eli Lilly, Johnson & Johnson, and AbbVie Right Now ↗

July 29, 2026

Via The Motley Fool

This Stock Has Skyrocketed 125% in 2026 -- and Billionaire Stanley Druckenmiller Is Loading Up on It ↗

July 17, 2026

Via The Motley Fool

Better Growth Buy: Axsome vs Revolution Medicines ↗

July 09, 2026

Via The Motley Fool

European Medicines Agency Expedites Assessment of Revolution Medicines’ Daraxonrasib Under Phased Review Process

July 07, 2026

From Revolution Medicines, Inc.

Via GlobeNewswire

These 3 Stocks Trounced the S&P 500 in the First Half of 2026 -- and Wall Street Thinks 1 of Them Could Soar Even More ↗

July 06, 2026

Via The Motley Fool

Revolution Medicines Is Up Nearly 140% in 2026. Is the Hot Biotech Stock Still a Buy? ↗

July 05, 2026

Via The Motley Fool

Revolution Medicines Has a $40 Billion Market Cap and Generates No Revenue. Here's Why That's Not Absurd. ↗

July 01, 2026

Via The Motley Fool

Can Revolution Medicines Be a Game-Changer Stock? ↗

June 11, 2026

Via The Motley Fool

Revolution Medicines Is Up 97% This Year: Here Are the Bull and Bear Cases for This Soaring Biotech Stock. ↗

June 05, 2026

Via The Motley Fool

Platform Biotech Models Draw Investor Eyes as Drug-Delivery Markets Head Toward $410 Billion

June 03, 2026

Via Investor Brand Network

NetworkNewsBreaks – Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Featured in BioMedWire Editorial on Advanced Drug Delivery and Platform-Based Biotech Innovation

June 03, 2026

Via Investor Brand Network

Platform Biotech Models Draw Investor Eyes as Drug-Delivery Markets Head Toward $410 Billion

June 03, 2026

From BioMedWire

Via GlobeNewswire

Biotech Fund Sells $44.5 Million Erasca Stake After Massive 700% Rally ↗

May 18, 2026

Via The Motley Fool

Boxer Capital’s $18 Million Corvus Pharma Bet Signals Confidence in This Biotech’s Next Phase ↗

May 17, 2026

Via The Motley Fool

Why One Healthcare Fund Increased Its Kodiak Sciences Stake Amid an Eye-Popping Rally ↗

May 17, 2026

Via The Motley Fool

Frequently Asked Questions

Is Revolution Medicines, Inc. - Common Stock publicly traded?

Yes, Revolution Medicines, Inc. - Common Stock is publicly traded.

What exchange does Revolution Medicines, Inc. - Common Stock trade on?

Revolution Medicines, Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for Revolution Medicines, Inc. - Common Stock?

The ticker symbol for Revolution Medicines, Inc. - Common Stock is RVMD on the Nasdaq Stock Market

What is the current price of Revolution Medicines, Inc. - Common Stock?

The current price of Revolution Medicines, Inc. - Common Stock is 211.38

When was Revolution Medicines, Inc. - Common Stock last traded?

The last trade of Revolution Medicines, Inc. - Common Stock was at 08/25/26 04:00 PM ET

What is the market capitalization of Revolution Medicines, Inc. - Common Stock?

The market capitalization of Revolution Medicines, Inc. - Common Stock is 22.47B

How many shares of Revolution Medicines, Inc. - Common Stock are outstanding?

Revolution Medicines, Inc. - Common Stock has 22B shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.